| Literature DB >> 34993946 |
Shivanand Pudakalakatti1, Priyank Raj1,2, Travis C Salzillo1,2, José S Enriquez1,2, Dontrey Bourgeois1,3, Prasanta Dutta1, Mark Titus4, Shayan Shams5, Priya Bhosale2,6, Michael Kim2,7, Florencia McAllister2,8, Pratip K Bhattacharya9,10.
Abstract
There is an unmet need for noninvasive surrogate markers that can help identify premalignant lesions across different tumor types. Here we describe the methodology and technical details of protocols employed for in vivo 13C pyruvate metabolic imaging experiments. The goal of the method described is to identify and understand metabolic changes, to enable detection of pancreatic premalignant lesions, as a proof of concept of the high sensitivity of this imaging modality.Entities:
Keywords: 13C; Assessment of preventive responses; Early detection; HP-MR; Hyperpolarization; MRI; Metabolic imaging; Premalignancy
Mesh：
Substances：
Year: 2022 PMID： 34993946 PMCID： PMC9352438 DOI： 10.1007/978-1-0716-2014-4_12
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745